Skip to main content

Drug Interactions between anifrolumab and bortezomib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

bortezomib anifrolumab

Applies to: bortezomib and anifrolumab

GENERALLY AVOID: The use of anifrolumab, a type 1 interferon (IFN) receptor antagonist antibody with other biologic therapies, including B-cell-targeted therapies may increase the risk of infections. Anifrolumab alone has been reported to increase the risk of infections, including serious and fatal infections. However, concomitant use of anifrolumab with these therapies has not been studied. In the randomized, double-blind, placebo-controlled, phase 3 study of anifrolumab in adult subjects with active Systemic Lupus Erythematosus (SLE) (n=365), if patients had received treatment with a biologic agent, or a B-cell-depleting agent (e.g., ocrelizumab, ofatumumab, obinutuzumab, rituximab), they were required to complete a wash-out period of at least 5 half-lives prior to enrolment in the study.

MANAGEMENT: Until further information is available, anifrolumab is not recommended for use in combination with biologics with immunosuppressant effects, including B-cell-targeted therapies such as ocrelizumab, ofatumumab, obinutuzumab, or rituximab.

References (1)
  1. (2022) "Product Information. Saphnelo (anifrolumab)." AstraZeneca Pty Ltd

Drug and food interactions

Moderate

bortezomib food

Applies to: bortezomib

GENERALLY AVOID: Data from in vitro and animal (mice) studies suggest that green tea may antagonize the cytotoxic effects of bortezomib. Polyphenols in green tea such as (-)-epigallocatechin gallate (EGCG) have been shown to block the proteasome inhibitory action of bortezomib in multiple myeloma and glioblastoma cancer cell lines. The mechanism appears to involve a direct chemical reaction between the boronic acid moiety of bortezomib and the 1,2-benzenediol groups present in certain polyphenols leading to inactivation of bortezomib. However, one group of investigators reported that no antagonism of bortezomib was observed in preclinical in vivo experiments where EGCG plasma concentrations are commensurate with dietary or supplemental intake.

MANAGEMENT: Until more data are available, it may be advisable to avoid or limit consumption of green tea and green tea products during treatment with bortezomib. The interaction has not been demonstrated for other, non-boronic acid proteasome inhibitors.

References (3)
  1. Bannerman B, Xu L, Jones M, et al. (2011) "Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea." Cancer Chemother Pharmacol, 68, p. 1145-54
  2. Golden EB, Lam PY, Kardosh A, et al. (2009) "Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors." Blood, 113, p. 5927-37
  3. Jia L, Liu FT (2013) "Why bortezomib cannot go with 'green'?" Cancer Biol Med, 10, p. 206-13

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer